New Data Shows Which Bladder Cancer Patients Benefit Most From Avelumab

A major clinical trial identified specific patient subgroups most likely to survive longer with the immunotherapy avelumab as a first-line maintenance treatment for advanced bladder cancer. The findings could help oncologists better target the expensive drug to patients most likely to respond, improving outcomes while managing healthcare costs.

Originaltitel: Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial